[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hot-flashes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hot-flashes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,47,82,107,136,157,187,219,245,272,310,336,355,378,402,434,457,483,505,526,563,586],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100454163","hot-flashes-and-neurovascular-function-in-women-100454163",false,"NCT05193968","Hot Flashes and Neurovascular Function in Women","Inclusion Criteria:\n\n* Non-smokers.\n* Non-obese.\n* Have at least one ovary.\n* Free from cardiovascular disease.\n* Not taking medications influencing cardiovascular function.\n\nExclusion Criteria:\n\n\\- None.",true,"FEMALE","40 Years","60 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Women who experience hot flashes are at greater risk for hypertension and other cardiovascular disease. Neurovascular control mechanisms are likely to play an important role in this relationship. As such, these studies are designed to provide a major step forward in understanding the link between hot flashes and neurovascular dysfunction and, by extension, cardiovascular disease in women.",[27,28,29],"Hot Flashes","Menopause","Vasomotor System; Labile",[31,32,33],"Neurovascular function","Autonomic function","Microvascular Function","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2022-02-24",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Mayo Clinic","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100634119","a-feasibility-study-of-biometric-measurements-via-wearable-smart-watch-technology-for-evaluation-of-vasomotor-symptoms-in-patients-treated-with-androgen-deprivation-therapy-for-prostate-cancer-prostate-007-100634119","NCT07535541","A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)","A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (BioWEAR)","BioWEAR","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male (biologic sex), aged ≥18 years of age\n4. Diagnosis of prostate cancer\n5. Must be receiving active treatment with ADT at the time of enrollment\n\n   a. ADT is defined as any medical or surgical intervention intended to lower the serum testosterone to \\\u003C50 mg\u002FdL for the purpose of treating prostate cancer\n6. Evidence of castrate level testosterone by either of the following:\n\n   1. A documented serum testosterone level of \\\u003C50 ng\u002FdL at any time point since initiation of ADT or\n   2. A documented decrease in PSA following initiation of ADT and no evidence of PSA progression per PCWG3 criteria (PSA progression defined as a rise in PSA of ≥25% from PSA nadir and absolute increase of ≥1 ng\u002FmL confirmed by a second measurement at least 3 weeks later)\n7. Duration of ADT expected to extend for a minimum of 4 weeks from time of study enrollment\n8. Report experiencing VMS that began after initiation of ADT and occur with a minimum frequency of once per day\n9. Own a smartphone with Bluetooth 5 compatibility and be willing to use cellular data and\u002For Wi-Fi on their smartphone. Participants must agree to download the Empatica Care app on their smartphone.\n\n   1. iPhone 8 or higher with iOS 16.0 or higher\n   2. Android devices version 12, 12.1, 13, 14, 15, or higher\n10. Ability to read, speak, and understand English\n11. ECOG performance status of 0, 1, or 2\n\nExclusion Criteria:\n\n1. Wrist circumference less than 95 mm or greater than 222 mm\n2. Known allergic reactions to components of the EmbracePlus smart watch, specifically any skin allergy to silicone\n3. Presence of VMS prior to initiation of ADT, regardless of severity or duration\n4. Active febrile illness (temperature \\>38°C) or on active treatment for febrile illness\n5. Inability to press button on smart watch crown\n6. Those receiving any experimental therapy for treatment of their prostate cancer (other standard of care prostate cancer therapies are permitted)\n7. Evidence of progression of prostate cancer as defined by PCWG3 criteria","MALE","18 Years",{"count":58,"type":21},18,[24],"The purpose of this study is to find out if patients with prostate cancer who have vasomotor symptoms, commonly called hot flashes, from their Androgen Deprivation Therapy (ADT) will consistently wear a smartwatch device to track their health data, log hot flashes on their smartwatch, and how these data compare with daily surveys about their hot flashes. Participants will be asked to wear the smartwatch for 4 weeks and to log their hot flashes on their smart watch pressing a button on the watch. Participants will be asked to complete surveys (sent through a text message link) to describe their experiences with hot flashes.",[62,27],"Prostate Cancer",[64,65,66,62,67,68,69,70,71,72],"VMS","Hot flashes","ADT","vasomotor symptoms","vasomotor symptom event","Smartwatch","Survey","EMA","androgen deprivation therapy","2026-06-05",{"date":75,"type":38},"2026-06-09",{"date":77,"type":38},"2026-05-21",{"date":79,"type":21},"2027-05",{"name":81,"class":45},"University of Virginia",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":56,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100637145","comparing-acupuncture-vs-sham-acupuncture-for-the-management-of-hot-flashes-in-prostate-cancer-patients-receiving-hormone-therapy-100637145","NCT07594002","Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy","Inclusion Criteria:\n\n* Patients with history of prostate cancer with currently receiving hormone therapy or had received hormone therapy in the past two years\n* Hormone therapies may include androgen deprivation therapy ( ADT; e.g., leuprolide, degarelix, or relugolix) or androgen signaling inhibitors (e.g., enzalutamide, apalutamide, or darolutamide) or adrenal steroid synthesis inhibitor (e.g., abiraterone acetate).\n* Patients may also receive additional treatments such as chemotherapy, radioligand therapy or target therapy in combination with hormone therapy.\n* Reports hot flashes at least twice per day. Patients may already be taking medications for hot flashes. There is no limit on the number of hot flash medications they can be using.\n* ECOG performance status =3 (see Appendix A).\n* Patients may participate in other therapeutic clinical trials for the treatment of prostate cancer. They will remain eligible as long as they meet the eligible criteria.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with a prior or concurrent malignancy are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Patients can't travel for acupuncture\n* Patients with high bleeding tendency as determined by PI","ALL","99 Years",{"count":91,"type":21},40,[24],"This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life.\n\nParticipants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits.\n\nThe primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer.",[95,62,96,27],"Accupuncture","Hormone Therapy",[62,27,98],"Androgen Deprivation Therapy","NOT_YET_RECRUITING",{"date":101,"type":38},"2026-05-27",{"date":73,"type":21},{"date":104,"type":21},"2028-05-31",{"name":106,"class":45},"University of Kentucky",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100638244","a-study-in-canada-to-follow-outcomes-of-women-in-menopause-treated-with-fezolinetant-for-hot-flashes-when-given-in-clinical-practice-100638244","NCT07602530","A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice","A Real-world Observational Study of Outcomes Among Canadian Women With Bothersome VMS Associated With Menopause Who Are Treated With Fezolinetant in a Real-life Setting According to Routine Healthcare Practice","CANDLELIGHT","Inclusion Criteria:\n\n* Participant lives in Canada.\n* Participant is experiencing VMS associated with menopause.\n* Participant is newly prescribed fezolinetant as part of routine clinical care but has not yet initiated the first dose. The decision to prescribe fezolinetant must be made prior to and independent of study participation.\n* Participant has acceptable hepatic function test results within the past 3 months prior to taking the first dose as described in the fezolinetant label.\n* Participant is a fluent speaker of English or French.\n* Participant is able to use digital devices and has access to an internet-capable device such as a mobile device or computer.\n\nExclusion Criteria:\n\n* A participant will be excluded if they have contraindications as described in the fezolinetant label.\n* A participant will be excluded if they were previously treated with fezolinetant by a physician.\n* A participant will be excluded if they have been clinically diagnosed with a sleep disorder (e.g., insomnia, narcolepsy) and\u002For is taking medication to improve a sleep disorder not associated with VMS (i.e., a participant with sleep disturbance associated with VMS is eligible).\n* A participant will be excluded if they are currently participating in an interventional study or previously participated in another interventional study within 6 months of the first dose of fezolinetant.",{"count":116,"type":21},238,"OBSERVATIONAL","This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS). Their own doctor has prescribed fezolinetant for hot flashes and night sweats, as part of routine health care in Canada.\n\nIn this study, women will be taking tablets of fezolinetant. This study is about recording information only. The women's own doctor decides on treatment, not the study sponsor (Astellas).\n\nWomen are taking fezolinetant every day for up to 52 weeks (1 year). The main aim is to learn if fezolinetant improves hot flashes and night sweats after 12 weeks. Other aims are to learn if fezolinetant improves hot flashes and night sweats throughout the study. This includes improved sleep and the women's wellbeing. Details are recorded on how satisfied the women are with fezolinetant and if they completed their treatment. This includes reasons for stopping treatment. Any safety issues are recorded. Details about other treatments taken before or with fezolinetant are also recorded.",[27],[121,67,122,123,124],"Menopausal symptoms","ESN364","fezolinetant","VEOZAH®","2026-05-14",{"date":127,"type":38},"2026-05-22",{"date":129,"type":38},"2025-10-23",{"date":131,"type":21},"2027-11-30",{"name":133,"class":134},"Astellas Pharma Europe Ltd.","INDUSTRY",2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":46},"100458569","the-cardiovascular-impact-of-hot-flushes-100458569","NCT05251324","The Cardiovascular Impact of Hot Flushes","Inclusion Criteria:\n\n* Postmenopausal (may have or may not have hot flushes)\n* Have not started hormone therapy and\u002For will discontinue hormone therapy for the duration of the study\n\nExclusion Criteria:\n\n* Reported nicotine\u002Ftobacco use within the last six months\n* Diabetic or asthmatic\n* Diagnosed significant carotid stenosis\n* History of significant autonomic dysfunction, heart disease, respiratory disease, or severe neurologic condition such as stroke or traumatic brain injury\n* Existing metabolic or endocrine abnormalities\n* Use of heart\u002Fblood pressure medications that are determined to interfere with study outcomes\n* Unwilling to discontinue use of OC (or other hormonal contraceptives, including intrauterine devices or contraceptive implants) and\u002For MHT\n* Pregnant or breastfeeding\n* Unwilling or unable to refrain from consuming caffeine or alcohol in the 12 hours before visit two or three\n* Unwilling or unable to refrain from vigorous exercise (at least 10 minutes in duration) in the 12 hours before visit two or three\n* Unwilling or unable to fast in the eight hours before visit two or three\n* Body mass index greater than or equal to 35 kg\u002Fm\\^3","70 Years",{"count":144,"type":21},60,"The overall objective of this study is to examine the physiological responses that occur during a hot flush in postmenopausal women. The following specific aims will be executed to reach the overall objective of this study. Aim 1: To determine if hot flushes can be reliably induced with a temperature-controlled, water- circulating (TCWC) heating pad. Based on previous research, the investigators hypothesize that hot flushes will be inducible with the TCWC in symptomatic women, but not in asymptomatic women. Aim 2: To determine if heat-induced hot flushes in symptomatic women will cause reproducible cardiovascular and respiratory responses. The investigators hypothesize that heat-induced hot flushes produce similar and reproducible cardiovascular and respiratory responses to spontaneous hot flushes. Aim 3: To determine if body fat percentage influences hot flush severity or frequency during spontaneous or induced hot flushes. The investigators hypothesize that women with higher body fat have reduced hot flash severity and frequency.",[27,28],[28],"2026-04-30",{"date":150,"type":38},"2026-05-07",{"date":152,"type":38},"2022-03-01",{"date":154,"type":21},"2027-05-26",{"name":156,"class":45},"University of Minnesota",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":46},"100464708","acupuncture-withwithout-self-acupressure-for-post-oophorectomy-hot-flashes-in-brca-carriers-100464708","NCT05331209","Acupuncture With\u002FWithout Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers","Acupuncture With or Without Self-acupressure for Hot Flashes in Post-oophorectomy Patients With BRCA Mutations: A Prospective, Randomized Controlled Trial","BRCA","Inclusion Criteria:\n\n* Female carriers of the BRCA 1 and 2 genes\n* age ≥ 25 years\n* after risk-reducing salpingo-oophorectomy\n* reporting ≥ 5 hot flashes per day\n\nExclusion Criteria:\n\n* Patients not fulfilling the study inclusion criteria will be excluded from participation","25 Years",{"count":167,"type":21},200,[24],"Risk-reducing surgery with salpingo-oophorectomy (RRSO) is the standard recommended treatment for all female carriers of BRCA genes 1 and 2. The post-surgical menopause induced is invariably accompanied by hot flashes and other symptoms, which can severely impair quality of life and function. Hormone-replacement therapy (HRT) is the standard conventional treatment for these symptoms, though these drugs do not always provide adequate relief and many patients either cannot receive them due to a diagnosis of breast cancer or hypercoagulable state; or are unwilling to take them due to their concern about the associated increased risk for developing hormone-induced breast cancer.\n\nAcupuncture and acupressure have been researched extensively and shown to be both safe and effective in reducing hot flashes in post-menopausal patients and in those with breast cancer receiving anti-hormonal drugs.\n\nThe present study will examine the effectiveness of acupuncture, with\u002Fwithout self-acupressure, on 200 post- RRSO patients who suffer from at least 5 hot flashes per day, including those treated with HRT. All participants will receive 8 weekly treatments with acupuncture, and then randomly assigned to receive (or not) self-administered acupressure, to be performed daily at home. The response to the study interventions will be assessed using daily Hot Flash Scores, the Menopause Specific Quality of Life (MenQoL) and Measure Yourself Concerns and Wellbeing (MYCAW) questionnaires (at baseline; at the end of the 8-week intervention; and at 16 weeks). The safety of the study treatments will be assessed throughout.",[27,171],"Menopause Surgical",[173,174,175,176,177],"acupuncture","acupressure","hot flashes","surgical menopause","quality of life","2026-04-23",{"date":180,"type":38},"2026-04-29",{"date":182,"type":21},"2026-12-01",{"date":184,"type":21},"2028-12-31",{"name":186,"class":45},"Shaare Zedek Medical Center",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":203,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":46},"100633931","the-effect-of-cold-packs-on-hot-flushes-and-depression-in-women-going-through-the-climacteric-period-100633931","NCT07533097","The Effect of Cold Packs on Hot Flushes and Depression in Women Going Through the Climacteric Period","The Effect of Applying Cold Gel Packs to the LI4 and SP6 Acupoints on Menopausal Hot Flashes and Depression in Women During the Climacteric Period","Inclusion Criteria:\n\n* In the perimenopausal phase (no menstruation for 3-11 months or an increase in irregular menstrual bleeding) or the postmenopausal phase (no menstruation for more than 12 months),\n* Participants experiencing moderate to severe hot flushes at least four times a day in the week prior to enrolment,\n* Participants who are literate in Turkish and able to communicate,\n* Participants who volunteer to take part in the study will be included in the study.\n\nExclusion Criteria:\n\n* Women who have entered menopause following surgery,\n* Women whose hot flush symptoms have decreased or ceased in the week prior to joining the study,\n* Those receiving hormone replacement therapy,\n* Those who had received herbal medication (such as black cohosh, black cohosh, ginkgo, ginseng, motherwort, valerian, black snake root, St. John's wort, etc.) or chemical medication for at least two weeks prior to joining the study,\n* Women with endocrine system disorders such as diabetes or a condition presenting symptoms similar to hot flushes,\n* Women with a regular menstrual cycle,\n* Women with a psychiatric diagnosis who are currently receiving treatment,\n* Women taking sleeping pills,\n* Women with a language barrier preventing communication in Turkish,\n* Women who are not willing to participate in the study will not be included in the research.",{"count":195,"type":21},80,[24],"This study is planned as a pre-post test, randomised controlled, experimental trial designed to determine the effect of applying a cold gel pack to the Sanyinjiao (SP6) and Hegu (Large Intestinal 4 (LI4)) acupoints on hot flushes and depression in women during the climacteric period.",[27,199,200,201,202],"Climactericum","Perimenopausal Depression","Cold Application","Acupoints",[204,175,205,206,207,208,209],"Climacterium","perimenopausal depression","cold gel packs","cold application","LI4 acupoint","SP6 acupoint","2026-04-16",{"date":212,"type":38},"2026-04-21",{"date":214,"type":21},"2026-04-13",{"date":216,"type":21},"2026-09-13",{"name":218,"class":45},"Rabia Atilla",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":15,"sex":16,"minAge":226,"maxAge":18,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":46},"100573206","improving-sympathetic-activity-hot-flashes-and-sleep-in-midlife-women-using-inspiratory-muscle-strength-training-100573206","NCT06743269","Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women Using Inspiratory Muscle Strength Training","Time-efficient Inspiratory Muscle Strength Training for Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women","Inclusion Criteria:\n\n* Females aged 45-60 with hot flashes.\n* Participants will be recruited from Rochester, MN and surrounding areas.\n* Non-smokers.\n* BMI \\\u003C 40kg\u002Fm\\^2.\n* No history of cardiovascular disease, except for hypertension.\n\nExclusion Criteria:\n\n* Detailed medical and social histories will be collected. To allow for ecological validity, participants will not be excluded for use of menopausal hormone therapy or medications affecting cardiovascular function so long as they have been on a consistent regimen for ≥3 months and during the study period. This approach to medications is consistent with recent work in this area.\n* Participants will be screened for contraindications to inspiratory muscle strength training including, a history of spontaneous pneumothorax, collapsed lung that has not healed fully, a perforated eardrum that has not healed fully, and\u002For any other condition of the eardrum.\n* Additional exclusion criteria will include the use of sleep aids (i.e., prescription, melatonin, doxylamine, valerian root, etc.).","45 Years",{"count":228,"type":21},30,[24],"The purpose of this research is to understand how training the muscles used for breathing (inhalation) affects menopausal hot flashes, sympathetic nerve activity and sleep.",[28,27,232],"Blood Pressure Regulation",[234,235,236,175],"menopause","blood pressure","inspiratory training","2026-03-24",{"date":239,"type":38},"2026-03-30",{"date":241,"type":38},"2025-03-27",{"date":243,"type":21},"2027-01",{"name":44,"class":45},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":46},"100615571","a-randomized-controlled-trial-of-acupuncture-for-the-management-of-hot-flashes-in-patients-with-hormone-receptor-positive-breast-cancer-100615571","NCT07294339","A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer","针刺治疗激素受体阳性乳腺癌患者潮热的随机对照试验研究，A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer","ACU-HRBC-HF","Inclusion Criteria Female patients aged 18 to 75 years. Histopathologically confirmed breast cancer, currently receiving endocrine therapy (e.g., selective estrogen receptor modulators and\u002For aromatase inhibitors, CDK4\u002F6 inhibitors), with or without ovarian function suppression, for at least 4 weeks and ongoing at the time of enrollment.\n\nExpected survival time \\> 6 months. Experiencing persistent hot flashes for at least 4 weeks, with a frequency of ≥14 episodes per week (≥2 per day) during the week prior to enrollment, and a Hot Flash Composite Score (HFCS) of 3-4.\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1:\n\n0: Fully active, able to carry on all pre-disease performance without restriction;\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out light work (e.g., housework, office work);\n2. Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours;\n3. Capable of only limited self-care; confined to bed or chair more than 50% of waking hours;\n4. Completely disabled; cannot carry on any self-care; totally confined to bed or chair;\n5. Dead. Willing and able to participate in the study and sign the informed consent form.\n\nExclusion Criteria Evidence of tumor metastasis, currently undergoing radiotherapy, chemotherapy, or having a planned surgery.\n\nUse of selective serotonin reuptake inhibitors (SSRIs) and\u002For anticonvulsants or other pharmacologic agents for hot flash management within 4 weeks prior to study entry.\n\nUnstable cardiac disease or myocardial infarction within 6 months prior to study initiation.\n\nRecent initiation or modification of endocrine therapy within 1 week, or planned initiation or modification within 14 weeks.\n\nHistory or risk of seizure of unclear etiology. Prior acupuncture treatment for hot flashes within 6 months before enrollment. Contraindications to MRI scanning. Pregnant or lactating women. Presence of uncontrolled active infection. Severe psychiatric disorders or family history of psychiatric or neurological diseases.\n\nWithdrawal Criteria Failure to complete acupuncture treatment per protocol, making efficacy evaluation impossible.\n\nUse of medications or treatments during the trial that may affect study outcomes.\n\nVoluntary withdrawal from the study during treatment.\n\nDiscontinuation Criteria Serious adverse events, complications, or physiological changes during treatment that make continuation unsafe or impractical.\n\nLoss to follow-up or death after enrollment. Participant's voluntary withdrawal at any stage of treatment.","75 Years",{"count":144,"type":21},[24],"Hot flashes are among the most common and distressing adverse effects experienced by patients receiving endocrine therapy for hormone receptor-positive breast cancer. Hormone replacement therapy (HRT) and non-hormonal medications can alleviate symptoms but are limited by side effects and safety concerns, leading to poor adherence. Acupuncture, a traditional Chinese medical therapy involving percutaneous stimulation of specific acupoints, has shown potential to reduce the frequency and severity of hot flashes with minimal adverse events.\n\nThis randomized, parallel-controlled clinical trial aims to evaluate the efficacy and safety of acupuncture in managing hot flashes in postoperative breast cancer patients undergoing endocrine therapy. Sixty eligible patients with stage I-III hormone receptor-positive breast cancer will be randomly assigned in a 1:1 ratio to receive either true acupuncture or sham acupuncture, three times per week for eight weeks, followed by a 16-week follow-up period without acupuncture. Functional magnetic resonance imaging (fMRI) will be employed to explore neural mechanisms underlying acupuncture's effects, alongside assessments of hot flash frequency, quality of life (FACT-B+ES), sleep quality (PSQI), and serum biomarkers related to endocrine and neuropeptide regulation. The results are expected to provide evidence for the efficacy and central mechanisms of acupuncture in managing hot flashes in breast cancer patients.",[258,259,27],"Acupuncture Treatment","Hormone Receptor-Positive Breast Cancer",[259,27,261,262],"Acupuncture","Randomized Controlled Trial","2026-03-18",{"date":265,"type":38},"2026-03-19",{"date":267,"type":21},"2026-04-01",{"date":269,"type":21},"2027-10-01",{"name":271,"class":45},"Peking University People's Hospital",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":283,"conditions":284,"keywords":301,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":46},"100589690","phase-2-proof-of-concept-trial-to-assess-the-efficacy-and-safety-of-fezolinetant-in-improving-vasomotor-symptoms-in-men-with-prostate-cancer-undergoing-androgen-deprivation-therapy-100589690","NCT06957691","Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)","Fezo-ADT","Inclusion Criteria:\n\n* Male sex\n* Age 40 years and older\n* Diagnosis of prostate cancer\n* Androgen deprivation therapy\n* Presence of 5 or more moderate-to-severe hot flashes per day or 35 or more moderate-to-severe hot flashes per week\n* Ability to sign the inform consent\n* Willing to use reliable methods of contraception if partner is of childbearing age\n* Ability to record hot flashes electronically\n\nExclusion Criteria:\n\n* Use of abiraterone acetate\n* Use of docetaxel and other chemotherapeutic agents\n* Liver cirrhosis\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of normal\n* Total bilirubin above the upper limit of normal\n* Glomerular filtration rate \\\u003C 30 mL\u002Fmin\n* Use of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, sedatives, or hypnotics\n* Use of over-the-counter hormonal agents or herbal compounds\n* Current use of CYP1A2 inhibitors\n* Ingestion of alcohol within 2 weeks prior to the baseline visit\n* Inability to abstain from alcohol use during the study period.",{"count":144,"type":21},[282],"PHASE2","The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.\n\nThe main questions it aims to answer are:\n\n* Does fezolinetant improve the frequency and severity of hot flashes?\n* Does fezolinetant cause any harm to the liver?\n* Does fezolinetant improve quality of life, sleep quality, fatigue, mood, sexual function, and metabolic parameters?\n\nResearchers will compare how people respond to fezolinetant versus a placebo, which does not contain any active medicine.\n\nParticipants will:\n\n* Take fezolinetant or a placebo every day for 4 weeks\n* Visit the clinic once every 2 weeks for checkups and tests\n* Keep a diary of the number of times and intensity that they experience hot flashes",[62,285,286,287,288,289,290,291,292,293,294,295,296,98,297,298,27,299,300],"Prostate Cancer (Adenocarcinoma)","Prostate Cancer Metastatic Disease","Prostate Cancer Recurrent","Prostate Carcinoma","Prostate Neoplasm","Prostate Adenocarcinoma","Prostate Cancer With Bone Metastasis","Vasomotor Disturbance","Vasomotor Symptoms","Vasomotor Symptoms (VMS)","Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men","Vasomotor Symptoms; Hot Flashes","Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma","Androgen-deprivation Therapy","Hot Flushes","Hot Flushes and\u002For Sweats",[98,27,299,62,293],"2026-03-05",{"date":304,"type":38},"2026-03-09",{"date":306,"type":38},"2026-01-14",{"date":184,"type":21},{"name":309,"class":45},"Shehzad Basaria, M.D.",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":46},"100173348","phase-2-solifenacin-compared-to-clonidine-for-reducing-hot-flashes-among-breast-cancer-patients-100173348","NCT01530373","Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients","A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy","Inclusion Criteria:\n\n* Women with a history of invasive breast cancer or DCIS\n* Currently taking aromatase inhibitors or tamoxifen\n* Not receiving hormone replacement therapy for minimum of one month\n* Age 18 years or older\n* Self-reported hot flashes at least fourteen times per week\n* Self-reported hot flashes for at least one month\n* If receiving non-tricyclic antidepressants (venlafaxine, paroxetine, citalopram, sertraline, etc.) or gabapentin, no change in regimen in past 4 weeks.\n\nExclusion Criteria:\n\n* Receiving any other treatment for hot flashes within the past month, including estrogens, progestins, androgens, or gabapentin.\n* Current use of clonidine or solifenacin. (If patients have been off of these for one month, then they are eligible)\n* History of severe renal or moderate or severe hepatic impairment, as indicated by physical exam and medical record\n* Concurrent or planned chemotherapy or radiotherapy (within next 3 months)\n* Currently receiving tricyclic antidepressants, monoamine oxidase inhibitors, barbiturates, pimozide.\n* Currently using CYP3A4 inducers (i.e., aminoglutethimide, carbamazepine, dexamethasone, efavirenz, ethosuximide, griseofulvin, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, phenytoin, primidone, rifabutin, rifampin, rifapentine, St. John's Wort, sulfadimidine, sulfinpyrazone, troglitazone) or potent CYP3A4 inhibitors (i.e., chloramphenicol, clarithromycin, erythromycin, imatinib mesylate, indinavir sulfate, itraconazole, ketoconazole, nefazoldone, nelfinavir mesylate, ritonavir, telithromycin, troleandomycin).\n* Uncontrolled or poorly controlled narrow-angle glaucoma, urinary retention, gastric retention (evaluated from history \\& physical exam and medical record)\n* Hypotension or uncontrolled hypertension (160\u002F95 \\> BP \\\u003C 100\u002F60)\n* Severe coronary insufficiency, conduction disturbances, recent myocardial infarction (within past 3 months), cerebrovascular disease, syncope (evaluated from history \\& physical and medical record)\n* History of allergy or adverse reactions to clonidine or solifenacin\n* ECOG status \\> 2 (in bed more than 50% of day)",{"count":318,"type":21},110,[282],"Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).",[27,322],"Breast Cancer",[175,324,325,326,327,177],"breast cancer","aromatase inhibitors","solifenacin","clonidine","2026-03-03",{"date":302,"type":38},{"date":331,"type":4},"2012-02",{"date":333,"type":21},"2028-09",{"name":335,"class":45},"University of Arkansas",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":342,"maxAge":18,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":46},"100625200","effect-of-high-power-laser-acupuncture-on-post-menopausal-hot-flashes-100625200","NCT07419542","Effect of High Power Laser Acupuncture on Post Menopausal Hot Flashes","Inclusion Criteria:\n\n* Sixty post menopausal women suffering from hot flashes.\n* Their age will range from 50 to 60 years.\n* Their body mass index (BMI) will range(\\> 30kg\u002Fm2).\n\nExclusion Criteria:\n\n* Breast cancer.\n* Myocardial infarction.\n* Pulmonary embolism.","50 Years",{"count":144,"type":21},[24],"The aim of this study will be to determine the effect of high power laser acupuncture on post menopausal hot flashes.",[27],"2026-02-12",{"date":349,"type":38},"2026-02-19",{"date":351,"type":21},"2026-02-20",{"date":148,"type":21},{"name":354,"class":45},"Cairo University",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":15,"sex":55,"minAge":226,"maxAge":18,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":4},"100623858","effect-of-a-mindfulness-based-stress-reduction-program-on-hot-flashes-and-sleep-quality-in-menopausal-women-a-randomized-controlled-trial-100623858","NCT07402096","Effect of a Mindfulness-Based Stress Reduction Program on Hot Flashes and Sleep Quality in Menopausal Women: A Randomized Controlled Trial","MBSR-MENO","Inclusion Criteria:\n\n* \\- Women aged between 45 and 60 years\n* Postmenopausal status defined as at least 12 months since the last menstrual period\n* Presence of hot flashes\n* Poor sleep quality (Pittsburgh Sleep Quality Index score \\>5)\n* Ability to understand and complete questionnaires\n* Access to the internet and ability to use a smartphone or computer for online sessions\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Current use of hormone replacement therapy\n\n  * Use of psychiatric medications\n  * Diagnosis of a psychiatric disorder\n  * Severe hearing or visual impairment\n  * Previous participation in mindfulness-based or yoga programs\n  * Incomplete baseline assessments\n  * Failure to attend intervention sessions",{"count":363,"type":21},90,[24],"Menopause is a natural transition characterized by vasomotor symptoms such as hot flashes and sleep disturbances, which can significantly impair quality of life. Non-pharmacological interventions are increasingly recommended for women who cannot or prefer not to use hormone therapy. Mindfulness-Based Stress Reduction (MBSR) is a structured behavioral intervention that has shown beneficial effects on stress-related symptoms and sleep quality; however, evidence regarding its effects on menopausal symptoms remains limited.\n\nThis randomized controlled trial aims to evaluate the effectiveness of an 8-week MBSR program on hot flash frequency and severity and sleep quality in menopausal women. A total of 90 menopausal women will be randomly assigned to either an intervention group receiving the MBSR program or a control group receiving no intervention. Participants in the intervention group will attend weekly sessions and engage in mindfulness practices, including breathing awareness, body scan, and stress management techniques.\n\nPrimary outcomes include changes in hot flash frequency and severity and sleep quality, assessed using validated self-report measures. The findings of this study are expected to contribute to evidence-based, non-pharmacological management strategies for menopausal symptoms.",[28,27,367],"Sleep Wake Disorders",[28,27,369],"Non-pharmacological intervention","2026-02-03",{"date":372,"type":38},"2026-02-11",{"date":374,"type":21},"2026-05-15",{"date":42,"type":21},{"name":377,"class":45},"Inonu University",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":46},"100618715","men-with-prostate-cancer-optimizing-wellness-by-enhanced-relief-from-hot-flashes-with-acupuncture-100618715","NCT07335224","Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture","MPOWER: A Pilot Trial Among Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture","MPOWER","Inclusion Criteria:\n\n* Male\n* At least 18 years of age\n* Histologically or cytologically confirmed adenocarcinoma of prostate of any stage I-IV\n* Undergoing androgen deprivation therapy (ADT) and\u002For androgen receptor pathway inhibitors\n* Experiencing moderate to severe daily interference from hot flashes, as indicated by the Hot Flash Related Daily Interference Scale (score≥4)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Able to read, understand, and provide written informed consent\n\nExclusion Criteria:\n\n* Severe or uncontrolled concurrent disease, infection or co-morbidity that, in the opinion of the Investigator, would make the patient inappropriate for enrollment\n* Known hypersensitivity to the acupuncture needles\n* Any condition that in the opinion of the Investigator would impair the patients' ability to comply with the study procedures\n* Unable to comply with study requirements\n* Use of acupuncture for hot flashes within 6 months prior to enrollment",{"count":387,"type":21},24,[24],"Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.",[27,391,293,98,392],"Acupuncture Therapy","Prostatic Neoplasms","2026-02-02",{"date":395,"type":38},"2026-02-04",{"date":397,"type":38},"2026-01-08",{"date":399,"type":21},"2027-06-30",{"name":401,"class":45},"Inova Health Care Services",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":15,"sex":16,"minAge":342,"maxAge":142,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":419,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":46},"100611276","jds-hf30-supplementation-on-menopause-related-quality-of-life-outcomes-in-postmenopausal-women-100611276","NCT07238478","JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women","Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of JDS-HF3.0 in Menopause Related Quality of Life Outcomes in Postmenopausal Women","Inclusion Criteria:\n\n1. Healthy biological females who are 50-70 years of age (inclusive).\n2. Have a body mass index (BMI) between 18.5 to 34.9 kg\u002Fm2 (inclusive).\n3. Self-reported as postmenopause. Defined as 12 months without a menstrual cycle in individuals who undergo \"Natural\" Menopause (Not Surgically or medically induced) and who have self-reported menopausal outcomes for the past 6 months.\n4. Have self-reported menopause related joint outcomes of moderate or severe severity according to a perceived discomfort greater or equal to 5 and less than 10 on a scale of 0-10 (participants rating their discomfort 5-9 will be included).\n5. Have self-reported \\> or equal to 4 hot flashes on average per day.\n6. In good general health (no active or uncontrolled diseases or conditions) and able to consume the study product.\n7. Agree to refrain from treatments listed in Section 6.5 in the defined timeframe.\n8. Have reliable, stable access to Wi-Fi and a smart phone\u002Fdevice.\n9. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n1. Individuals who are lactating, pregnant, or planning to become pregnant during the study.\n2. Active participation in a clinical trial.\n3. Use of any treatment for menopausal outcomes or other concomitant treatments for menopausal symptoms, joint health or at the discretion of the investigator. (Participants may be deemed ineligible at the discretion of the investigator if the medication may cause adverse interaction.)\n4. Have a known sensitivity, intolerability, or allergy to any of the study product or their excipients.\n5. Use of Glucosamine and\u002For Chondroitin for joint outcomes in the last 3 months prior to screening.\n6. Received a COVID-19 vaccine in the 2 weeks prior to screening or during the study period, current COVID-19 infections or currently have the post-COVID-19 condition as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnosis).\n7. Have a positive medical history of heart disease, renal disease, hepatic impairment, or active systemic infection (i.e., Lyme disease, TB, HIV).\n8. History of cancer (except localized skin cancer without metastases) within two (2) years prior to screening.\n9. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study or influence the results or the potential subject's ability to participate in the study.\n10. History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (i.e., Crohn's disease, short bowel, acute or chronic pancreatitis, gastric bypass procedures, or pancreatic insufficiency).\n11. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).\n12. Major surgery in three months prior to screening or planned major surgery during the study.\n13. History of alcohol or substance abuse in the last 5 years.\n14. Has evidence of inflammatory rheumatic disease or other diagnosed anti-inflammatory disease.\n15. Has evidence of autoimmune disease(s).\n16. Chronic use of curcumin or curcuminoids in an herbal or dietary supplement. Note: Screened participants that are willing to undergo a washout period of at least 3 months prior to participation in the trial can be enrolled.\n17. Chronic pain medication and use of analgesics specifically for joint-related discomfort (i.e. Opiates, Tramadol) Note: Screened participants that are willing to undergo a washout period of at least 2 weeks during the duration of the trial can be enrolled.\n18. Have severe joint and\u002For severe bone deformities.\n19. Diagnosed bone fractures.\n20. Are a candidate for surgical joint replacement.",{"count":410,"type":21},250,[24],"The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70. The primary research question is whether taking the study product daily for 12 weeks can reduce the severity and frequency of menopause-related symptoms.",[414,415,416,27,417,418,293],"Joint Discomfort","Joint Pain, Stiffness, Function","Joint Pain","Hot Flash","Night Sweats",[420,421,293,422,27,416,414,423,424],"Postmenopausal","Post menopause","Night sweats","Non-hormonal Treatment","Supplement","2025-11-18",{"date":427,"type":38},"2025-11-20",{"date":429,"type":38},"2025-05-14",{"date":431,"type":21},"2026-10",{"name":433,"class":134},"Bonafide Health",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":22,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":46},"100582531","evaluation-of-the-beneficial-effects-of-a-product-containing--aminobutyric-acid-gaba-on-climacteric-syndrome-disorders-100582531","NCT06864520","Evaluation of the Beneficial Effects of a Product Containing Γ-aminobutyric Acid (GABA) on Climacteric Syndrome Disorders","Valutazione Degli Effetti Benefici Di Un Prodotto Contenente Acido Γ-ammino Butirrico (GABA) Sui Disturbi Della Sindrome Climaterica CLIMATERICA","GABAPAUSE","Inclusion Criteria:\n\n* Physiological or iatrogenic menopause (amenorrhea for at least 12 months or for 6 months with FSH ≥40 IU\u002FL)\n* Greene Index value ≥ 15\n\nExclusion Criteria:\n\n* Patients who do not consent to the study\n* Patients who have used hormone replacement therapy in the last 3 months\n* Patients who have used phytotherapeutics in the last 3 months\n* Patients who have used acupuncture in the last 3 months\n* Uncompensated hyper or hypothyroidism\n* Acute phase of endocrine pathologies\n* Patients with major psychiatric disorders\n* Addiction to opioids or alcohol\n* Glaucoma\n* Active liver disease\n* Use of antidepressants, benzodiazepines or any neuroactive drug\n* Known allergy to the components of the treatment being studied",{"count":443,"type":21},112,[24],"The goal of this clinical trial is to learn if the food supplement based on GABA works to treat climateric symptoms. It will also learn about the safety of supplement based on GABA. The main question aims to answer:\n\n* Does food supplement based on GABA lower the climateric symptoms, such as hot flashes, sleep, disturbances, mood swings?\n* The supplement that will be administered is commonly available on the market and can be used without particular precautions. No important side effects are reported.\n\nResearchers will compare supplement based on GABA to a placebo (a look-alike substance that contains no active ingredients) to see if supplement based on GABA works to treat climateric symptoms.\n\nParticipants will:\n\n* Take supplement based on GABA or a placebo every day for 3 months\n* Visit the clinic on day 7, 37 and 97 after enrolment for checkups and tests\n* Keep a diary of number and intensity of hot flashes\n* To fill scales evaluating sleep quality, anxiety, depression and quality of life",[447,27],"Climacteric Symptoms","2025-03-04",{"date":450,"type":38},"2025-03-07",{"date":452,"type":38},"2023-10-25",{"date":454,"type":21},"2025-12",{"name":456,"class":45},"Ospedale Policlinico San Martino",{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":470,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":135},"100518426","strength-and-aerobic-training-against-hot-flushes-in-postmenopausal-women-100518426","NCT06030388","Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women","STrength and AeRobic Training Against Vasomotor Symptoms (START) in Postmenopausal Women","START","Inclusion Criteria:\n\n* Postmenopausal women (one of: ≥ 12 months since last menstruation; amenorrhea due to intrauterine device or hysterectomy and Follicle Stimulating Hormone (FSH) \\>30 mIU\u002Fml; bilateral oophorectomy; induced menopause due to chemotherapy or radiation and ≥2 years amenorrhea);\n* ≥ 28 moderate to severe hot flushes per week during a 2-week screening period, registered through a daily VMS diary;\n* Age ≥45 years;\n* Physical ability to participate in strength training or high intensity aerobic exercise for 60 minutes, 3 times\u002Fweek during 15 weeks;\n* Understand Swedish orally and in writing\n\nExclusion Criteria:\n\n* Regular physical activity \\>30 minutes per week of vigorous intensity or ≥150 minutes of moderate intensity or combined activities representing maximum 150 minutes of moderate intensity;\n* Use of systemic menopausal hormone therapy the last 2 months;\n* Use of natural preparations such as herbal preparations for VMS, or other medications for VMS the last 2 months;\n* Capillary hemoglobin \\\u003C110 g\u002Fl;\n* Blood pressure \\>160 mmHg systolic or \\>100 mmHg diastolic;\n* Unstable medical condition with a potential to affect VMS (like unregulated thyroid disease);\n* Medical condition that by a physician is judged not appropriate (because of potential to affect VMS or risk of injury with vigorous exercise)",{"count":363,"type":21},[24],"The goal of this randomised controlled trial is to investigate the effects of and compare two modes of physical exercise (strength training and high-intensity aerobic exercise) to unchanged physical activity on vasomotor symptoms (hot flushes) in postmenopausal women. The main question it aims to answer is the effect of 15 weeks of strength training vs high intensity aerobic training vs unchanged physical activity on frequency and severity of hot flushes. Participants will be randomised to:\n\n1. strength training\n2. high-intensity aerobic training\n3. untreated control group.\n\nResearchers will compare strength training, high-intensity aerobic training and untreated control group to see if training can reduce hot flushes.",[469,27],"Postmenopausal Symptoms",[471,472],"aerobic training","strength training","2025-01-20",{"date":475,"type":38},"2025-01-22",{"date":477,"type":38},"2023-09-12",{"date":479,"type":21},"2032-12",{"name":481,"class":482},"Linkoeping University","OTHER_GOV",{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":15,"sex":16,"minAge":226,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":46},"100571154","efficacy-and-safety-of-shatavari-for-treatment-of-menopausal-symptoms-in-women-a-randomized-double-blind-three-arm-parallel-placebo-controlled-study-100571154","NCT06716554","Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study","Inclusion Criteria:\n\n1. Menopausal women aged 45 to 65 years with intact uterus and ovaries.\n2. Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months, or reported menopause for at least 60 days\n3. Females with complaints of menopausal symptoms, e.g., hot flash, insomnia, migraine, easy irritation, etc.\n4. Body mass index 18-35 kg\u002Fm2\n5. Subject who has given written informed consent to participate in the study and understand the nature of the study\n6. Able to read and write in English or any other vernacular language\n7. No plan to commence new treatments over the study period.\n8. Must have the ability and willingness to sign an informed consent and to comply with all study procedures.\n\nExclusion Criteria:\n\n1. Participants taking any form of herbal extract in the last 3 months before study entry.\n2. Participants who are on hormone replacement therapy (HRT) for more than 3 months.\n3. Participants with Present active medical, surgical, and gynaecological problems.\n4. Participants with a history of alcohol, tobacco dependence, or any substance abuse\n5. Participants who had undergone bilateral ovariectomy\n6. Participants with history of breast or cervical carcinoma\n7. Participants who taking medication that affect bone metabolism, including glucocorticoid, anticonvulsant, and methotrexate.\n8. Participants with Clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study result difficult\n9. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study\n10. Participants with evidence of uncooperative attitude, including poor compliance.\n11. Participants with inability to attend follow-up visit\n12. Participants with any other medical condition (for example uncontrolled infection) that may, in the opinion of the Investigator, interfere with the study objective.\n13. Patients with known hypersensitivity to Ashwagandha.\n14. Patients who had participated in other clinical trials during the previous 3 months.\n15. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol","55 Years",{"count":491,"type":21},51,[24],"This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participants will then be asked to either take one capsule containing Shatavari or Shatavari + Ashwagandha or Placebo orally once daily in the morning after breakfast with a glass of water for 8 weeks. All the subjects will be asked to continue their routine diet and physical activities during the whole study period. The primary objective is to compare the efficacy of shatavari for treatment of menopausal symptoms in women. The secondary objective is to compare the safety of shatavari for treatment of menopausal symptoms in women.",[28,27,495],"Mood","2024-11-29",{"date":498,"type":38},"2024-12-04",{"date":500,"type":38},"2024-10-26",{"date":473,"type":21},{"name":503,"class":504},"SF Research Institute, Inc.","NETWORK",{"id":506,"slug":507,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":489,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":46},"100554455","reflexology-versus-acupressure-on-sleep-disturbance-and-hot-flashes-100554455","NCT06499311","Reflexology Versus Acupressure on Sleep Disturbance and Hot Flashes","Effect of Foot Reflexology Versus Acupressure on Sleep Disturbance and Hot Flashes in Postmenopausal Women","Inclusion Criteria:\n\n* Age ranged from 45 to 55 years old.\n* Their body mass index ranged from 25 to 3 kilograms per meter square.\n* Postmenopausal women suffering from moderate to sever hot flashes assessed by Hot Flashes Questionnaire.\n* Postmenopausal women suffering from sleep disturbances more than five assessed by Pittsburgh sleep quality index.\n\nExclusion Criteria:\n\n* Any emotional stress during at least 6 months.\n* Any pharmacological medicines lead to sleep disturbances.\n* Any mental disorders affect their sleep cycle.\n* Taking hormone replacement therapy for the past six months.\n* Using herbal medicine to improve menopausal symptoms severity.\n* Circular job in particular night shifts.\n* Sensorineural problems in their feet.",{"count":513,"type":21},54,[24],"World health Organization (WHO) estimates that by 2030, 1.2 billion women will be over 50 years old. With a prevalence of 70%, a hot flash is the most distressing symptoms associated with menopause. Postmenopausal associated sleep disturbances could affect those women social activities and one's daily positive functioning. Therefore, some patients and their providers seek alternative treatments such as relaxation techniques, acupressure, yoga, reflexology, regular exercise, balanced nutrition, herbal supplements, appropriate clothing, and frequent showers, have been shown to be effective in reducing symptoms associated with depression. So, this study will be the first one in this issue. Therefore, it will have valuable benefits in physical therapy field and scientific research.",[517,27],"Postmenopausal Flushing","2024-07-11",{"date":520,"type":38},"2024-07-12",{"date":522,"type":38},"2024-07-01",{"date":524,"type":21},"2024-08-20",{"name":354,"class":45},{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":15,"sex":88,"minAge":56,"maxAge":4,"enrollmentInfo":533,"targetDuration":342,"studyType":117,"phases":4,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":46},"100553518","virtual-peri-menopause-registry-of-australia-100553518","NCT06487130","Virtual perI-\u002FMenopause Registry of AusTrALia","VITAL","Inclusion Criteria:\n\n* Any Australian over 18 years of age.\n\nExclusion Criteria:\n\n* None.",{"count":534,"type":21},10000,"13 million (50.7%) Australians are born with ovaries, 14% (\\~3 million) are currently aged 40-59 yrs, \\& all such who live to midlife will experience menopause, defined as \\>12 months without a period. Peri-menopause (peri), typically occurs 5 yrs before menopause as hormone levels decrease. As with oestrogen, peri symptoms can affect every bodily system; e.g. depression\u002Fanxiety, diminished mental function, irregular periods, hot flushes, sleep problems, vaginal atrophy \\& urinary urgency. These symptoms are linked with lower quality of life \\& significantly higher work impairment; a third experiencing symptoms so severe as to impede daily life \\& increase risk of suicide. Lifetime increased risks of diabetes, heart disease, osteoporosis \\& dementia are also associated with menopause, yet it remains disconcertingly poorly studied.\n\nThe investigators propose to create a world-first, cutting-edge, consumer-driven, Virtual peri-\u002Fmenopause registry of AusTrALia (VITAL). The unique design will enable consumers to determine VITAL's questions, encourage secure revelation of private data e.g. vaginal \\& mental health symptoms, \\& to direct priorities for research, education, \\& health service improvements. VITAL will thus deliver optimal assessments of incidence, prevalence \\& impact.\n\nThe participating consumers, researchers, clinical specialists, policy makers, \\& modern virtual data infrastructure enable this unique \\& innovative registry design, future translation to improved community health, \\& promote awareness \\& collaborative synergies. Leveraging the investigators' critical range of expertise \\& ongoing feedback opportunities for both participants \\& stakeholder partnerships, the investigators will create a ground-breaking platform that:\n\n* empowers the consumer voice and priorities,\n* enables peri-\u002Fmenopause research to extend beyond existing niche focuses,\n* evidences the true impact of peri-\u002Fmenopause across the nation,\n* evolves healthcare services and outcomes, \\&\n* educates community, clinicians, \\& policy-makers. After Australian registry establishment, the investigators will expand VITAL to mirror it in other nations while still protecting individual's data the right way, but so all can learn \\& apply the best aspects of care from across the world.",[28,537,469,538,539,540,541,542,543,544,545,546,547,548,549,550,27,551,552,553],"Perimenopausal Disorder","Health Knowledge, Attitudes, Practice","Healthy Aging","Health Care Utilization","Health Care Seeking Behavior","Mental Health Impairment","Mental Deterioration","Mental Health Issue","Osteoporosis, Postmenopausal","Diabetes Mellitus Risk","Diabetes Mellitus, Type 2","Dementia","Cardiovascular Diseases","Menopause Related Conditions","Hot Flushes Aggravated","Economic Burden","Social Stigma","2024-07-02",{"date":556,"type":38},"2024-07-05",{"date":558,"type":38},"2023-08-03",{"date":560,"type":21},"2073-08",{"name":562,"class":134},"Bespoke Clinical Research",{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":16,"minAge":570,"maxAge":253,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":46},"100486394","study-of-acupuncture-in-the-treatment-of-hot-flashes-in-patients-with-hormone-receptor-positive-breast-cancer-100486394","NCT05613504","Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.","A Randomized Controlled Trial Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.","Inclusion Criteria:\n\n* Aged 30-75 years old;\n* Adjuvant hormone therapy (eg, tamoxifen and\u002For aromatase inhibitors) with or without ovarian function suppression has been administered for at least 4 weeks and is currently on treatment;\n* Patients with persistent hot flashes for at least 4 weeks and with a frequency of more than 14 hot flashes per week (2 times per day) in the week before inclusion in the study, the weekly average hot flash composite score is 3-4;\n* Patients after surgery and chemotherapy (if any);\n* Eastern Cooperative Oncology Group score of 0-1 points.\n* Sign the informed consent and participate in the clinical observation voluntarily.\n\nExclusion Criteria:\n\n* Tumor metastases, undergoing chemoradiotherapy or planning surgery;\n* Pharmacological intervention for hot flashes with hot flash treatment drugs such as selective serotonin reuptake inhibitors (SSRIs) and\u002For anticonvulsants for at least 4 weeks prior to study initiation;\n* Patients receiving phytoestrogens, tibolone or analogs, verapril, or specific homeopathic medicines;\n* Started or changed adjuvant hormone therapy within the past week, or who planned to start or change adjuvant hormone therapy in the past 14 weeks, pregnant or breastfeeding patients;\n* Bleeding or coagulation disorders with obvious uncontrolled infection\n* Psychiatric illness or family history; neurological disorder or family history; seizure possibility or history of seizures.","30 Years",{"count":363,"type":21},[24],"This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation mechanism of acupuncture intervention on hot flashes based on integrated PET\u002FMRI technology.",[27,322,261],[324,261,576,65],"Integrated PET\u002FMRI technology","2022-11-11",{"date":579,"type":38},"2022-11-16",{"date":581,"type":21},"2022-12-01",{"date":583,"type":21},"2027-12-01",{"name":585,"class":45},"Nanjing University of Traditional Chinese Medicine",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":568,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":253,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":46},"100474662","acupuncture-for-hot-flashes-in-patients-with-hormone-receptor-positive-breast-cancer-100474662","NCT05460819","Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.","Inclusion Criteria:\n\n* Aged 18-75 years old;\n* Adjuvant hormone therapy (eg, tamoxifen and\u002For aromatase inhibitors) with or without ovarian function suppression has been administered for at least 4 weeks and is currently on treatment;\n* Vasomotor syndrome for at least 6 weeks;\n* Premenopausal or postmenopausal patients;\n* Patients with persistent hot flashes for at least 4 weeks and with a frequency of more than 14 hot flashes per week (2 times per day) in the week before inclusion in the study, the weekly average hot flash composite score is 3-4;\n* Patients after surgery and after chemotherapy (if any);\n* Eastern Cooperative Oncology Group score of 0-1 points.\n* Sign the informed consent and voluntarily participate in this clinical observation.\n\nExclusion Criteria:\n\n* Tumor metastases, undergoing chemoradiotherapy or planning surgery;\n* Pharmacological intervention for hot flashes with hot flash treatment drugs such as selective serotonin reuptake inhibitors (SSRIs) and\u002For anticonvulsants for at least 4 weeks prior to study initiation;\n* Unstable heart disease or myocardial infarction within 6 months prior to study start;\n* Started or changed adjuvant hormone therapy within the past week, or who planned to start or change adjuvant hormone therapy in the past 14 weeks;\n* Seizures of unknown likelihood or history of seizures;\n* Have used acupuncture for hot flashes within 6 months prior to the start of the study;\n* Pregnant or breastfeeding patients;\n* Apparent uncontrolled infection;\n* Mental illness or family history; neurological disorder or family history.",{"count":363,"type":21},[24],"This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation mechanism of acupuncture intervention on hot flashes based on functional magnetic resonance imaging technology.",[27,322,261],[324,261,175,597],"Functional MRI","2022-07-19",{"date":600,"type":38},"2022-07-20",{"date":602,"type":21},"2022-08-01",{"date":604,"type":21},"2027-07-31",{"name":585,"class":45}]